​

​

Three Months Ended

​

Six Months Ended

​

​

June 30, 

​

June 30, 

Collaborative Arrangements Revenue

​

2026

  ​ ​ ​

2025

​

2026

  ​ ​ ​

2025

Linaclotide Collaboration and License Agreements:

​

​

​

​

​

​

​

​

​

​

​

​

AbbVie (North America)

​

$

110,912

​

$

86,425

​

$

216,022

​

$

125,819

AbbVie (Europe and other)

​

​

1,113

​

​

904

​

​

1,921

​

​

1,715

Astellas (Japan)

​

​

397

​

​

428

​

​

744

​

​

801

Grand Life Sciences ⁽¹⁾ (China, including Hong Kong and Macau)

​

​

79

​

​

74

​

​

158

​

​

162

Other Agreements:

​

​

​

​

​

​

​

​

​

​

​

​

Asahi Kasei Therapeutics Corporation (Japan)
(apraglutide)

​

​

540

​

​

(2,679)

​

​

702

​

​

(2,202)

Other

​

​

—

​

​

87

​

​

—

​

​

87

Total collaborative arrangements revenue

​

$

113,041

​

$

85,239

​

$

219,547

​

$

126,382